Sanaa Kamal

Summary

Affiliation: Cairo University
Country: Egypt

Publications

  1. ncbi Hepatitis C virus genotype 4 therapy: progress and challenges
    Sanaa M Kamal
    Department of Gastroenterology and Liver Disease, Ain Shams Faculty of Medicine, Cairo, Egypt
    Liver Int 31:45-52. 2011
  2. ncbi Hepatitis C genotype 4: What we know and what we don't yet know
    Sanaa M Kamal
    Department of Gastroenterology and Liver Disease, Ain Shams Faculty of Medicine, Cairo, Egypt
    Hepatology 47:1371-83. 2008
  3. ncbi Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response
    Sanaa M Kamal
    Department of Gastroenterology and Hepatology, Ain Shams University, Cairo, Egypt
    Hepatology 46:1732-40. 2007
  4. ncbi Immune modulation by helminthic infections: worms and viral infections
    S M Kamal
    Department of Tropical Medicine, Ain Shams Faculty of Medicine, Heliopolis, Cairo, Egypt
    Parasite Immunol 28:483-96. 2006
  5. ncbi Duration of peginterferon therapy in acute hepatitis C: a randomized trial
    Sanaa M Kamal
    Department of Gastroenterology and Liver Disease Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Hepatology 43:923-31. 2006
  6. ncbi Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response
    S M Kamal
    Department of Gastroenterology and Liver Disease, Ain Shams Faculty of Medicine, 22 Al Ahram St, Roxy, Heliopolis, Cairo, Egypt
    Gut 54:858-66. 2005
  7. ncbi Kinetics of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses in HCV and Schistosoma mansoni coinfection: relation to progression of liver fibrosis
    Sanaa M Kamal
    Department of Infectious Diseases, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
    J Infect Dis 189:1140-50. 2004
  8. ncbi Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients
    Sanaa M Kamal
    Department of Infectious Diseases, Harvard Institutes of Medicine, 4 Blackfan Circle, Boston, MA 02115, USA
    J Virol 78:12252-8. 2004
  9. ncbi Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C
    Sanaa M Kamal
    Department of Internal Medicine II, Gastroenterology and Hepatology, University of Freiburg, Germany
    Gastroenterology 123:1070-83. 2002
  10. ncbi Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response
    Sanaa M Kamal
    Division of Gastroenterology and Liver Disease Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Gastroenterology 130:632-8. 2006

Research Grants

  1. Features of HCV and Schistosoma mansoni coinfection
    Sanaa Kamal; Fiscal Year: 2004
  2. Cellular Immune Responses in Subjects Exposed to Hepatitis C
    Sanaa Kamal; Fiscal Year: 2007

Detail Information

Publications16

  1. ncbi Hepatitis C virus genotype 4 therapy: progress and challenges
    Sanaa M Kamal
    Department of Gastroenterology and Liver Disease, Ain Shams Faculty of Medicine, Cairo, Egypt
    Liver Int 31:45-52. 2011
    ....
  2. ncbi Hepatitis C genotype 4: What we know and what we don't yet know
    Sanaa M Kamal
    Department of Gastroenterology and Liver Disease, Ain Shams Faculty of Medicine, Cairo, Egypt
    Hepatology 47:1371-83. 2008
    ..Tailored treatment options that are comparable to the treatment approaches for genotype 1, 2, and 3 patients to optimize treatment for each patient are now being developed...
  3. ncbi Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response
    Sanaa M Kamal
    Department of Gastroenterology and Hepatology, Ain Shams University, Cairo, Egypt
    Hepatology 46:1732-40. 2007
    ..Conclusion: In patients with chronic hepatitis C genotype 4 and undetectable HCV RNA at weeks 4 and 12, treatment with PEG-IFN alpha-2b and ribavirin for 24 weeks and 36 weeks, respectively, is sufficient...
  4. ncbi Immune modulation by helminthic infections: worms and viral infections
    S M Kamal
    Department of Tropical Medicine, Ain Shams Faculty of Medicine, Heliopolis, Cairo, Egypt
    Parasite Immunol 28:483-96. 2006
    ....
  5. ncbi Duration of peginterferon therapy in acute hepatitis C: a randomized trial
    Sanaa M Kamal
    Department of Gastroenterology and Liver Disease Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Hepatology 43:923-31. 2006
    ..Duration of treatment should be further optimized based on genotype and rapid virologic response at week 4...
  6. ncbi Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response
    S M Kamal
    Department of Gastroenterology and Liver Disease, Ain Shams Faculty of Medicine, 22 Al Ahram St, Roxy, Heliopolis, Cairo, Egypt
    Gut 54:858-66. 2005
    ..The response rates and duration of peginterferon alpha (PEG-IFN-alpha) and ribavirin combination therapy in chronic hepatitis C genotype 4, the prevalent genotype in the Middle East and Africa, are poorly documented...
  7. ncbi Kinetics of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses in HCV and Schistosoma mansoni coinfection: relation to progression of liver fibrosis
    Sanaa M Kamal
    Department of Infectious Diseases, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
    J Infect Dis 189:1140-50. 2004
    ....
  8. ncbi Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients
    Sanaa M Kamal
    Department of Infectious Diseases, Harvard Institutes of Medicine, 4 Blackfan Circle, Boston, MA 02115, USA
    J Virol 78:12252-8. 2004
    ..This finding has important implications for HCV vaccine and therapeutic development...
  9. ncbi Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C
    Sanaa M Kamal
    Department of Internal Medicine II, Gastroenterology and Hepatology, University of Freiburg, Germany
    Gastroenterology 123:1070-83. 2002
    ..This study investigated if the greater efficacy of pegylated IFNs might be related to modulation of immunologic responses...
  10. ncbi Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response
    Sanaa M Kamal
    Division of Gastroenterology and Liver Disease Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Gastroenterology 130:632-8. 2006
    ..Initiation of treatment at week 8 or 12 results in higher sustained virologic rates than initiation at week 20...
  11. ncbi Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics
    Sanaa M Kamal
    Department of Infectious Diseases, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    Hepatology 39:1721-31. 2004
    ....
  12. ncbi Acute hepatitis C: prospects and challenges
    Sanaa M Kamal
    World J Gastroenterol 13:6455-7. 2007
    ....
  13. ncbi Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis
    Sanaa M Kamal
    Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Hepatology 43:771-9. 2006
    ..In conclusion, serial cytokine and fibrosis markers can accurately determine the rate at which fibrosis is progressing, identifying both those with rapid fibrosis and those with stable disease...
  14. ncbi Acute hepatitis C without and with schistosomiasis: correlation with hepatitis C-specific CD4(+) T-cell and cytokine response
    S M Kamal
    Department of Infectious Diseases, Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterology 121:646-56. 2001
    ..Immune responses during the first few months of acute hepatitis C virus (HCV) infection seem crucial for viral control, but the relationship of these responses to natural history is poorly characterized...
  15. ncbi Improving outcome in patients with hepatitis C virus genotype 4
    Sanaa M Kamal
    Harvard Institute of Medicine, Boston, Massachusetts 02115, USA
    Am J Gastroenterol 102:2582-8. 2007
    ..This review discusses the clinical data among patients with G4 and assesses the impact of an individualized approach on improved treatment outcomes in these patients...
  16. ncbi Acute hepatitis C: a systematic review
    Sanaa M Kamal
    Department of Gastroenterology and Liver Disease, Ain Shams Faculty of Medicine, Cairo, Egypt
    Am J Gastroenterol 103:1283-97; quiz 1298. 2008
    ..We scanned the literature for predictors of spontaneous resolution and treatment during the acute stage of HCV to identify factors that would assist in treatment decision making...

Research Grants4

  1. Features of HCV and Schistosoma mansoni coinfection
    Sanaa Kamal; Fiscal Year: 2004
    ..It is anticipated that investigating this pattern of viral-parasitic interaction will projects will provide useful information for development of more effective diagnostic, prevention and treatment strategies. ..
  2. Cellular Immune Responses in Subjects Exposed to Hepatitis C
    Sanaa Kamal; Fiscal Year: 2007
    ..Our long-term goal is to mimic this response to develop vaccine strategies or therapeutic protocols capable of preventing persistent hepatitis C infection. ..